Patents by Inventor Ann C. Horan
Ann C. Horan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110269216Abstract: This invention is directed to nucleic acids which encode the proteins that direct the synthesis of the orthosomycin everninomicin and to use of the nucleic acids and proteins to produce compounds exhibiting antibiotic activity based on the everninomycin structure. The DNA sequence for the gene clusters responsible for encoding everninomicin biosynthetic genes, which provide the machinery for producing everninomicin, are provided. Thus, this invention provides the nucleic acid sequences needed to synthesize novel everninomicin-related compounds based on everninomicin, arising from modifications of the DNA sequence designed to change glycosyl and modified orsellinic acid groups contained in everninomicin. A Micromonospora site-specific integrase gene is also provided, which can be incorporated in a vector for integration into any actinomycete, and, particularly into Monospora.Type: ApplicationFiled: May 2, 2011Publication date: November 3, 2011Applicant: Schering CorporationInventors: Thomas J. Hosted, Tim X. Wang, Ann C. Horan
-
Patent number: 7947480Abstract: This invention is directed to nucleic acids which encode the proteins that direct the synthesis of the orthosomycin everninomicin and to use of the nucleic acids and proteins to produce compounds exhibiting antibiotic activity based on the everninomycin structure. The DNA sequence for the gene clusters responsible for encoding everninomicin biosynthetic genes, which provide the machinery for producing everninomicin, are provided. Thus, this invention provides the nucleic acid sequences needed to synthesize novel everninomicin-related compounds based on everninomicin, arising from modifications of the DNA sequence designed to change glycosyl and modified orsellinic acid groups contained in everninomicin. A Micromonospora site-specific integrase gene is also provided, which can be incorporated in a vector for integration into any actinomycete, and, particularly into Monospora.Type: GrantFiled: September 3, 2010Date of Patent: May 24, 2011Assignee: Schering CorporationInventors: Thomas J. Hosted, Tim X. Wang, Ann C. Horan
-
Publication number: 20110027865Abstract: This invention is directed to nucleic acids which encode the proteins that direct the synthesis of the orthosomycin everninomicin and to use of the nucleic acids and proteins to produce compounds exhibiting antibiotic activity based on the everninomycin structure. The DNA sequence for the gene clusters responsible for encoding everninomicin biosynthetic genes, which provide the machinery for producing everninomicin, are provided. Thus, this invention provides the nucleic acid sequences needed to synthesize novel eveminomicin-related compounds based on eveminomicin, arising from modifications of the DNA sequence designed to change glycosyl and modified orsellinic acid groups contained in everninomicin. A Micromonospora site-specific integrase gene is also provided, which can be incorporated in a vector for integration into any actinomycete, and, particularly into Monospora.Type: ApplicationFiled: September 3, 2010Publication date: February 3, 2011Inventors: Thomas J. Hosted, Tim X. Wang, Ann C. Horan
-
Patent number: 7790411Abstract: This invention is directed to nucleic acids which encode the proteins that direct the synthesis of the orthosomycin everninomicin and to use of the nucleic acids and proteins to produce compounds exhibiting antibiotic activity based on the everninomycin structure. The DNA sequence for the gene clusters responsible for encoding everninomicin biosynthetic genes, which provide the machinery for producing everninomicin, are provided. Thus, this invention provides the nucleic acid sequences needed to synthesize novel everninomicin-related compounds based on everninomicin, arising from modifications of the DNA sequence designed to change glycosyl and modified orsellinic acid groups contained in everninomicin. A Micromonospora site-specific integrase gene is also provided, which can be incorporated in a vector for integration into any actinomycete, and, particularly into Monospora.Type: GrantFiled: April 25, 2007Date of Patent: September 7, 2010Assignee: Schering CorporationInventors: Thomas J. Hosted, Tim X. Wang, Ann C. Horan
-
Publication number: 20090004649Abstract: This invention is directed to nucleic acids which encode the proteins that direct the synthesis of the orthosomycin everninomicin and to use of the nucleic acids and proteins to produce compounds exhibiting antibiotic activity based on the everninomycin structure. The DNA sequence for the gene clusters responsible for encoding everninomicin biosynthetic genes, which provide the machinery for producing everninomicin, are provided. Thus, this invention provides the nucleic acid sequences needed to synthesize novel everninomicin-related compounds based on everninomicin, arising from modifications of the DNA sequence designed to change glycosyl and modified orsellinic acid groups contained in everninomicin. A Micromonospora site-specific integrase gene is also provided, which can be incorporated in a vector for integration into any actinomycete, and, particularly into Monospora.Type: ApplicationFiled: April 25, 2007Publication date: January 1, 2009Inventors: Thomas J. Hosted, Tim X. Wang, Ann C. Horan
-
Patent number: 7229813Abstract: This invention is directed to nucleic acids which encode the proteins that direct the synthesis of the orthosomycin everninomicin and to use of the nucleic acids and proteins to produce compounds exhibiting antibiotic activity based on the everninomycin structure. The DNA sequence for the gene clusters responsible for encoding everninomicin biosynthetic genes, which provide the machinery for producing everninomicin, are provided. Thus, this invention provides the nucleic acid sequences needed to synthesize novel everninomicin-related compounds based on everninomicin, arising from modifications of the DNA sequence designed to change glycosyl and modified orsellinic acid groups contained in everninomicin. A Micromonospora site-specific integrase gene is also provided, which can be incorporated in a vector for integration into any actinomycete, and, particularly into Monospora.Type: GrantFiled: December 23, 2004Date of Patent: June 12, 2007Assignee: Schering CorporationInventors: Thomas J. Hosted, Tim X. Wang, Ann C. Horan
-
Patent number: 7220567Abstract: Plasmid genes from Micromonospora carbonacea var. africana ATCC39149 pMLP1 have been isolated cloned, sequenced and functionally identified. These genes have been used to create vectors which integrate in a site-specific manner into the host chromosome of actinomycete species.Type: GrantFiled: May 15, 2001Date of Patent: May 22, 2007Assignee: Schering CorporationInventors: Thomas J. Hosted, Jr., Ann C. Horan
-
Patent number: 6861513Abstract: This invention is directed to nucleic acids which encode the proteins that direct the synthesis of the orthosomycin everninomicin and to use of the nucleic acids and proteins to produce compounds exhibiting antibiotic activity based on the everninomycin structure. The DNA sequence for the gene clusters responsible for encoding everninomicin biosynthetic genes, which provide the machinery for producing everninomicin, are provided. Thus, this invention provides the nucleic acid sequences needed to synthesize novel everninomicin-related compounds based on everninomicin, arising from modifications of the DNA sequence designed to change glycosyl and modified orsellinic acid groups contained in everninomicin. A. Micromonospora site-specific integrase gene is also provided, which can be incorporated in a vector for integration into any actinomycete, and, particularly into Monospora.Type: GrantFiled: January 11, 2001Date of Patent: March 1, 2005Assignee: Schering CorporationInventors: Thomas J. Hosted, Tim X. Wang, Ann C. Horan
-
Publication number: 20040101832Abstract: This invention is directed to nucleic acids which encode the proteins that direct the synthesis of the orthosomycin everninomicin and to use of the nucleic acids and proteins to produce compounds exhibiting antibiotic activity based on the everninomycin structure. The DNA sequence for the gene clusters responsible for encoding everninomicin biosynthetic genes, which provide the machinery for producing everninomicin, are provided. Thus, this invention provides the nucleic acid sequences needed to synthesize novel everninomicin-related compounds based on everninomicin, arising from modifications of the DNA sequence designed to change glycosyl and modified orsellinic acid groups contained in everninomicin. A. Micromonospora site-specific integrase gene is also provided, which can be incorporated in a vector for integration into any actinomycete, and, particularly into Monospora.Type: ApplicationFiled: January 11, 2001Publication date: May 27, 2004Inventors: Thomas J. Hosted, Tim X. Wang, Ann C. Horan
-
Patent number: 6569668Abstract: Plasmid genes from Micromonospora rosaria pMR2 have been isolated, cloned, sequenced and functionally identified. These genes have been used to create vectors which can be used to express actinomycete genes, manipulate metabolic pathways and produce useful gene products such as hybrid antibiotics.Type: GrantFiled: March 29, 2001Date of Patent: May 27, 2003Assignee: Schering CorporationInventors: Thomas J. Hosted, Jr., Ann C. Horan
-
Publication number: 20020076788Abstract: Plasmid genes from Micromonospora carbonacea var. africana ATCC39149 pMLP1 have been isolated cloned, sequenced and functionally identified. These genes have been used to create vectors which integrate in a site-specific manner into the host chromosome of actinomycete species.Type: ApplicationFiled: May 15, 2001Publication date: June 20, 2002Inventors: Thomas J. Hosted, Ann C. Horan
-
Publication number: 20020015989Abstract: Plasmid genes from Micromonospora rosaria pMR2 have been isolated, cloned, sequenced and functionally identified. These genes have been used to create vectors which can be used to express actinomycete genes, manipulate metabolic pathways and produce useful gene products such as hybrid antibiotics.Type: ApplicationFiled: March 29, 2001Publication date: February 7, 2002Inventors: Thomas J. Hosted, Ann C. Horan
-
Patent number: 6017894Abstract: Three novel macrolactam monosaccharides isolated from an antimicrobial complex 510 produced in fermentation under controlled conditions using a biologically pure culture of the microorganism Actinomadura fulva subsp. uruguayensis ATCC 53713.Type: GrantFiled: August 12, 1991Date of Patent: January 25, 2000Assignee: Schering CorporationInventors: Raymond Cooper, Ann C. Horan, Mahesh G. Patel, Imbi Truumees, Raymond F. Yarborough
-
Patent number: 5837691Abstract: A novel macrolactam monosaccharide isolated from an antimicrobial complex 517 produced in fermentation under controlled conditions using a biologically pure culture of the microorganism Actinomadura vulgaris subsp. vulgaris ATCC 53748.Type: GrantFiled: August 12, 1991Date of Patent: November 17, 1998Assignee: Schering CorporationInventors: Vinod R. Hegde, Ann C. Horan, Mahesh G. Patel, Ingrid-Agneta Gunnarsson
-
Patent number: 5618809Abstract: N-alkanoyl derivatives of staurospodne represented by the formula I ##STR1## wherein R.sub.a and R.sub.b are each H or ##STR2## wherein R.sub.1 and R.sub.2 are independently H or --OH or --OCH.sub.3 and R.sub.3 is OH, NHCH.sub.3, NCH COCH.sub.3 or NHCOCH.sub.3 and R.sub.4 is OH or H and, stereochemical isomers thereof with the provisos that (1) when R.sub.a and R.sub.b .dbd.A, and R.sub.1.dbd.H.sub.2 or OH R.sub.3 is not NHCH.sub.3 ; (2) when R.sub.a and R.sub.b.dbd. B, then R.sub.1 .dbd.R.sub.4 .dbd.OH or R.sub.1 .dbd.R.sub.4 .dbd.H; (3) when R.sub.a .dbd.R.sub.b .dbd.H R.sub.1 .dbd.--OCH.sub.3, and (4) when R.sub.a and R.sub.b .dbd.A, and R.sub.1 .dbd.H and R.sub.2 .dbd.OCH.sub.3, then R3 is not and ##STR3## pharmaceutical compositions thereof useful for inhibiting myosin light chain kinase, protein kinase C or tumor cell proliferation as well as producing an antihypertensive effect and an anti-inflammatory effect in warm-blood animals such as man are disclosed.Type: GrantFiled: February 27, 1995Date of Patent: April 8, 1997Assignee: Schering CorporationInventors: Ellen B. Barrabee, Ann C. Horan, Frank A. Gentile, Mahesh G. Patel
-
Patent number: 5494913Abstract: Compounds of the formulas: ##STR1## or pharmaceutically acceptable salts thereof. These compounds are obtainable by cultivation of a pure culture of Actinoplanes sp. SCC2314, ATCC 55600. These compounds are useful as antifungal agents.Type: GrantFiled: December 13, 1994Date of Patent: February 27, 1996Assignee: Schering CorporationInventors: Min Chu, Mahesh G. Patel, Ann C. Horan, Joseph Terracciano
-
Patent number: 5446207Abstract: Compounds of the formula: ##STR1## wherein a is a single bond and b is a double bond; or a is a double bond and b is a single bond; and enantiomers thereof; or a pharmaceutically acceptable salt thereof are described. These compounds can improve lipoprotein profile of dyslipidemic patients and generate an anti-atherogenic lipoprotein profile of normolipidemic individuals. In addition, inhibition of CETP activity may be useful as antifertility agents.Type: GrantFiled: September 1, 1993Date of Patent: August 29, 1995Assignee: Harbor Branch Oceanographic Institution, Inc.Inventors: Shirley A. Pomponi, Vincent P. Gullo, Ann C. Horan, Mahesh G. Patel, Stephen J. Coval
-
Patent number: 5420261Abstract: Two novel glycosides of 3'-deoxyaquayamycin isolated from an antimicrobial complex produced in fermentation under controlled conditions using a biologically pure culture of the microorganism Streptomyces sp. SCC 2136, ATCC 55186 are disclosed.Type: GrantFiled: May 29, 1992Date of Patent: May 30, 1995Assignee: Schering CorporationInventors: Min Chu, Ann C. Horan, Joseph A. Marquez, Mahesh G. Patel
-
Patent number: 5378626Abstract: Novel macrocyclic lactone antibacterials isolated from a culture containing the microorganism S. aerocolongenes sub sp. antibiotica SCC 1886, ATTC 55003 and their use for treating and/or preventing antibacterial infections, especially Chlamydia infections are disclosed.Type: GrantFiled: April 29, 1994Date of Patent: January 3, 1995Assignee: Schering CorporationInventor: Ann C. Horan
-
Patent number: 5352707Abstract: A method for treating airway congestion which comprises administering an effective amount of the compound of formula II which follows ##STR1## or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 26, 1992Date of Patent: October 4, 1994Assignee: Harbor Branch Oceanographic Institution, Inc.Inventors: Shirley A. Pompni, Vincent P. Gullo, Ann C. Horan, Mahesh G. Patel, Stephen Coval